The Pox-Protein Public-Private Partnership (P5) is tackling an enduring and daunting challenge: developing the world’s first HIV vaccine and ensuring it achieves maximum public health impact.
A large biotech firm needed support in developing an evidence-based policy narrative in preparation for the launch of a CAR T-cell therapy for a rare form of cancer.
The global headquarters of a top-5 pharmaceutical company needed to develop a global policy strategy to support the launch of a new treatment for influenza.
A US-based biotech company required support to identify, evaluate and prioritize novel immunotherapies and targeted oncology drug candidates to supplement its clinical pipeline.
To support a mid-stage clinical development program, a top-5 pharmaceutical company engaged Shift Health to obtain an understanding of physicians’ decision-making process with alternative therapies.
A global biopharmaceutical company recognized the need to work in partnership with healthcare systems in order to realize the vital, long-term potential of a personalized approach to healthcare.
An Asian specialty healthcare company needed to assess the US market for novel image guidance medical device systems for minimally invasive cardiac interventions.
A player in the medical cannabis space required support to uncover and catalogue scientific evidence that established the link between specific cannabis-based metabolites and their therapeutic benefit.
A top-5 global biopharmaceutical company wanted to identify promising oncology drug candidates that it could in-license or acquire to bolster its oncology franchise revenues over the near term.